LL-37 is the only human cathelicidin antimicrobial peptide and is studied in immune and antimicrobial research. Patients can request a telehealth evaluation through the TelosRX Telehealth Portal to discuss compounded access.
What Is LL-37?
LL-37 is a 37-amino-acid peptide derived from human cathelicidin. It is studied in preclinical research for antimicrobial and immune-modulating pathways.
LL-37 is not an FDA-approved drug. It is available through compounding pharmacies under valid prescription.
Common Discussion Points
Patients often raise LL-37 during evaluations for:
- Antimicrobial pathway research interest
- Immune modulation discussions
- Skin and barrier research
- Inflammation research applications
A licensed provider determines clinical appropriateness individually.
Pre-PCAC July 2026 Regulatory Context
LL-37 is under PCAC review ahead of the July 2026 meeting. Patients interested in compounded access should consult a licensed provider while it remains available.
How TelosRX Handles LL-37
TelosRX is an online-first telehealth service. Patient evaluation is asynchronous, and compounded medications are prepared through our licensed pharmacy partner.
- Step 1: Complete an asynchronous telehealth intake at TelosRX.
- Step 2: Licensed provider review.
- Step 3: Prescription issued if clinically appropriate.
- Step 4: Compounded LL-37 ships discreetly to your door.
Important Compliance Information
LL-37 is not FDA-approved. Compounded preparations are prepared under federal compounding regulations.
Prescriptions require evaluation by a licensed healthcare provider. Approval is not guaranteed. Individual results vary.
TelosRX operates under LegitScript-certified telehealth standards.
Start your private evaluation at TelosRX.